News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neurogen Says Insomnia Drug Safe In Phase I Trial
December 8, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Dec 8 (Reuters) - Neurogen Corp. (NRGN.O: Quote, Profile, Research) on Thursday said the results of its Phase I multiple ascending dose trial for insomnia drug NG2-73 showed that the compound was safe and well tolerated.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
Vaccines
Moderna’s mRNA Tech Could Boost Flu Shot Efficacy. Americans Will Have To Wait
February 16, 2026
·
3 min read
·
Annalee Armstrong
Rare diseases
‘Highly Impressive’ Data Propels BridgeBio’s Achondroplasia Drug Forward
February 12, 2026
·
2 min read
·
Tristan Manalac
Insights
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
February 12, 2026
·
1 min read
·
Jennifer Smith-Parker
Gene therapy
In Vivo Is Having a Moment as Cell and Gene Therapy Sector Gathers in San Diego
February 11, 2026
·
4 min read
·
Heather McKenzie
